| Sophie Warshaw, DPT | |
|
8011 112th Street Ct E, Puyallup, WA 98373-7814 | |
| (253) 848-0662 | |
| (253) 848-8567 |
| Full Name | Sophie Warshaw |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 7 Years |
| Location | 8011 112th Street Ct E, Puyallup, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134637176 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2081S0010X | Physical Medicine & Rehabilitation - Sports Medicine | PT60797104 (Washington) | Secondary |
| 225100000X | Physical Therapist | PT60797104 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Multicare Health System | 7719899897 | 1704 |
News Archive
The U.S. "ranks among the lowest in terms of the quality and effectiveness of its aid," according to a new Center for Global Development/Brookings Institution report, Foreign Policy's "The Cable" blog writes.
QRxPharma Limited announced today that the United States Patent and Trademark Office issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.
Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.
The recently passed health care reform legislation will require significant investment in IT solutions and system upgrades throughout its implementation. A new report, IT Implications of Health Care Reform, released by INPUT, predicts federal, state and local governments will need to invest more than $5 billion in health IT and traditional IT solutions in order to implement requirements of the new law.
Pressure BioSciences, Inc. today announced that scientists from two separate research groups presented data at the recent HUPO 11th Annual World Congress (Boston, MA) indicating that the incorporation of the Company's Pressure Cycling Technology Platform into their sample preparation processes resulted in a marked improvement in the quality and/or efficiency of test results.
› Verified 7 days ago
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
The U.S. "ranks among the lowest in terms of the quality and effectiveness of its aid," according to a new Center for Global Development/Brookings Institution report, Foreign Policy's "The Cable" blog writes.
QRxPharma Limited announced today that the United States Patent and Trademark Office issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.
Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.
The recently passed health care reform legislation will require significant investment in IT solutions and system upgrades throughout its implementation. A new report, IT Implications of Health Care Reform, released by INPUT, predicts federal, state and local governments will need to invest more than $5 billion in health IT and traditional IT solutions in order to implement requirements of the new law.
Pressure BioSciences, Inc. today announced that scientists from two separate research groups presented data at the recent HUPO 11th Annual World Congress (Boston, MA) indicating that the incorporation of the Company's Pressure Cycling Technology Platform into their sample preparation processes resulted in a marked improvement in the quality and/or efficiency of test results.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sophie Warshaw, DPT Po Box 5299, Ms: 820-5-pco, Tacoma, WA 98415-0299 Ph: () - | Sophie Warshaw, DPT 8011 112th Street Ct E, Puyallup, WA 98373-7814 Ph: (253) 848-0662 |
News Archive
The U.S. "ranks among the lowest in terms of the quality and effectiveness of its aid," according to a new Center for Global Development/Brookings Institution report, Foreign Policy's "The Cable" blog writes.
QRxPharma Limited announced today that the United States Patent and Trademark Office issued the Company a new patent, U.S. Patent #7,923,453, which expires in 2029. This patent covers a proprietary dosing algorithm for converting patients from intravenous opioid administration to orally administered MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.
Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.
The recently passed health care reform legislation will require significant investment in IT solutions and system upgrades throughout its implementation. A new report, IT Implications of Health Care Reform, released by INPUT, predicts federal, state and local governments will need to invest more than $5 billion in health IT and traditional IT solutions in order to implement requirements of the new law.
Pressure BioSciences, Inc. today announced that scientists from two separate research groups presented data at the recent HUPO 11th Annual World Congress (Boston, MA) indicating that the incorporation of the Company's Pressure Cycling Technology Platform into their sample preparation processes resulted in a marked improvement in the quality and/or efficiency of test results.
› Verified 7 days ago